For grade 1-2 toxicities between the groups, anti-CD47 mAbs were significantly more likely than selective SIRPα blockers to cause fever (12.9 vs 5.7%, p=0.042), chills (13.2 vs 8.1%, p=0.002), nausea/vomiting (14.5 vs 5.9%, p=0.005), headache (21.0 vs 4.9%, p=0.002), and anemia (20.5 vs 4.0%, p=0.0002). Here, CD47 is linked to anemia.